日前,云顶新耀宣布,其扩产补充申请已正式获得中国国家药品监督管理局(NMPA)批准。耐赋康作为IgA肾病治疗的一线基石药物,此次扩产获批将进一步提升产能,增加产品供应,更高效地响应中国及亚洲地区持续增长的临床需求。作为目前唯一获国内外指南共同推荐的IgA肾病对因治疗药物,该药物在医保放量背景下需求激增,随着市场需求的快速增长,其提升匹配产能的需求日益迫切。作为从瑞典Calliditas引进的产品,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.